Industry Projects | Projects by Region | Projects by Category | Archived Projects | Project Gallery
 

ASA404 Vascular Disrupting Agent for Solid Tumours



Tumour cross-section (diagram)

Antisoma's ASA404 is a vascular disrupting agent (VDA) that is designed to attack the established blood vessel network within a tumour.


Back to Project Details



Related Projects

Ariflo (Cilomilast) - Oral PDE-IV Inhibitor for
Ariflo (cilomilast) is an oral selective phosphodiesterase (PDE) IV...

Sativex - Investigational Cannabis-Based treatment for Pain and Multiple Sclerosis
Developed by GW Pharmaceuticals, Sativex is a whole plant medicinal...

Capravirine - Anti-Retroviral Drug
Developed by Pfizer Global Research and Development, capravirine is...

Acomplia (Rimonabant) - Investigational Agent for
Developed by Sanofi-Aventis, Acomplia (rimonabant) is a selective...

Tarceva - Small Molecule
Tarceva (erlotinib) is an oral anti-cancer drug developed by...

See all projects


Contact us
Advertise with us
Terms and conditions
Privacy
Links
Newsletter sign up
Online magazine sign up

drugdevelopment-technology.com is a product of Net Resources International. Copyright 2011 Net Resources International, a trading division of SPG Media Limited.